Research & Development
NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100 in treating suicidal depression
11 August 2025 - Biopharmaceutical company NRx Pharmaceuticals Inc (NASDAQ: NRXP) declared on Monday that it has received FDA Fast Track designation for NRX-100, its preservative-free intravenous keta...
IO Biotech reports Phase 3 trial results for Cylembio plus pembrolizumab in advanced melanoma
11 August 2025 - Denmark-based clinical-stage biopharmaceutical company IO Biotech (NASDAQ:IOBT) on Monday announced results from its pivotal Phase 3 IOB-013/KN-D18 trial evaluating Cylembio used in c...
Novartis reports positive Phase III results for ianalumab in Sjögren's disease
11 August 2025 - Swiss pharmaceutical company Novartis AG (SIX:NOVN) (NYSE:NVS) announced on Monday that its global Phase III NEPTUNUS-1 and NEPTUNUS-2 trials evaluating ianalumab (VAY736) in adults w...
Nuformix files US Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis
11 August 2025 - Pharmaceutical development company Nuformix plc (LSE:NFX) declared on Monday that it has submitted an application to the US Food and Drug Administration for Orphan Drug Designation (O...
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
11 August 2025 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that it has secured US Food and Drug Administration priority review for a supplemental New Drug Applicatio...
RemeGen receives FDA approval to advance RC148 into Phase II trials for solid tumours
8 August 2025 -

Chinese biopharmaceutical company RemeGen Co., Ltd. (SHA:688331, HKG:09995) announced on Friday that it has received clearance fro...